123696澳门论坛

Shanghai, China, March 28, 2024 – Genor Biopharma (Stock code: 6998.HK) announced today its 2023 annual financial results, business progress and other highlights in the past year.

China National Medical Products Administration (NMPA) has officially accepted the new drug application for GB491 (Lerociclib, cyclin-dependent kinase 4/6 inhibitor) combined with Letrozole for the treatment of HR-positive, HER2-negative patients with advanced breast cancer who have not previously undergone systemic antitumor therapy.

Genor Biopharma participated at the 65th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA on December 9-12, 2023, and shared the poster of the preliminary clinical safety and efficacy results of the phase I/II study of GB261(CD20/CD3).

Genor Biopharma has published preliminary dose escalation results from a phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in the December 1, 2023 issue of Molecular Cancer Therapeutics, an AACR journal

Genor Biopharma Co. Ltd participated at the 38th Annual Meeting of The Society for Immunotherapy of Cancer, 2023, in San Diego, shared two posters for two programs: Generation of an innovative BsAb targeting CCR8/CTLA-4, Development of a tri-specific antibody targeting PD-1/CTLA-4/TIGIT.